An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma was written by Alderuccio, Juan Pablo;Arcaini, Luca;Watkins, Marcus P.;Beaven, Anne W.;Shouse, Geoffrey;Epperla, Narendranath;Spina, Michele;Stefanovic, Alexandra;Sandoval-Sus, Jose;Torka, Pallawi;Alpert, Ash B.;Olszewski, Adam J.;Kim, Seo-Hyun;Hess, Brian;Gaballa, Sameh;Ayyappan, Sabarish;Castillo, Jorge J.;Argnani, Lisa;Voorhees, Timothy J.;Saba, Raya;Chowdhury, Sayan Mullick;Vargas, Fernando;Reis, Isildinha M.;Kwon, Deukwoo;Alexander, Jonathan S.;Zhao, Wei;Edwards, Dali;Martin, Peter;Cencini, Emanuele;Kamdar, Manali;Link, Brian K.;Logothetis, Constantine N.;Herrera, Alex F.;Friedberg, Jonathan W.;Kahl, Brad S.;Luminari, Stefano;Zinzani, Pier Luigi;Lossos, Izidore S.. And the article was included in Blood Advances in 2022.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:
Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin lymphoma. No consensus exists regarding the standard-of-care in patients with advanced-stage disease. Current recommendations are largely adapted from follicular lymphoma, for which bendamustine with rituximab (BR) is an established approach. We analyzed the safety and efficacy of frontline BR in EMZL using a large international consortium. We included 237 patients with a median age of 63 years (range, 21-85). Most patients presented with Eastern Cooperative Oncol. Group (ECOG) performance status 0 to 1 (n = 228; 96.2), stage III/IV (n = 179; 75.5), and intermediate (49.8) or high (33.3) Mucosa Associated Lymphoid Tissue International Prognosis Index (MALT-IPI). Patients received a median of 6 (range, 1-8) cycles of BR, and 20.3(n = 48) received rituximab maintenance. Thirteen percent experienced infectious complications during BR therapy; herpes zoster (4) was the most common. Overall response rate was 93.2with 81complete responses. Estimated 5-yr progression-free survival (PFS) and overall survival (OS) were 80.5(95CI, 73.1to 86) and 89.6(95CI, 83.1to 93.6), resp. MALT-IPI failed to predict outcomes. In the multivariable model, the presence of B symptoms was associated with shorter PFS. Rituximab maintenance was associated with longer PFS (hazard ratio = 0.16; 95CI, 0.04-0.71; P = .016) but did not impact OS. BR is a highly effective upfront regimen in EMZL, providing durable remissions and overcoming known adverse prognosis factors. This regimen is associated with occurrence of herpes zoster; thus, prophylactic treatment may be considered. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Electric Literature of C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem